Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
The current Vertex Pharmaceuticals(VRTX) stock price is $425.00, with a market capitalization of 107.87B. The stock trades at a price-to-earnings (P/E) ratio of 25.35.
During the trading session on 2026-05-07, Vertex Pharmaceuticals(VRTX) shares reached a daily high of $429.51 and a low of $423.59. At a current price of $425.00, the stock is +0.3% higher than the low and still -1.1% under the high.
Trading activity shows a volume of 953.42K, compared to an average daily volume of 1.15M.
The stock's 52-week range extends from a low of $362.50 to a high of $507.92.
The stock's 52-week range extends from a low of $362.50 to a high of $507.92.
VRTX News
Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $615 from $607 and keeps an Overweight rating on the shares. Unlock hedge fund-leve...
Vertex Pharmaceuticals (VRTX) Incorporated announced that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited thera...
Key Points Vertex Pharmaceuticals' core business isn't the growth driver it once was. The company has also found it hard to expand into new areas. However, t...
Analyst ratings
76%
of 34 ratingsMore VRTX News
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported mixed financial results for the first quarter after the market close on Monday. Vertex reported first-quarter...
The company's CF franchise shows strength, but investor focus is on the non-CF pipeline for additional growth opportunities, according to Needham. The Vertex Ph...
Vertex Pharmaceuticals Inc. ((VRTX)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level...
Image source: The Motley Fool. Monday, May 4, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Reshma Kewalramani Executive Vice President, Chi...
Vertex Pharmaceuticals stock is holding steady today. What’s the outlook for VRTX shares? Vertex Q1 Highlights Vertex reported first-quarter revenue of $2.99...
Reports Q1 revenue $2.99B, consensus $3.00B. “Vertex is off to a strong start in 2026, driven by leadership in cystic fibrosis; growth in sickle cell disease, b...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average a...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.